endpoints.news is our new home on June 1. endpts.com will still work, but the front door is now https://endpoints.news

A ge­net­ics test­ing out­fit is bail­ing on its CRO ser­vices, choos­ing in­stead to re­fo­cus around pre­ci­sion drugs

5 years ago
Deals
Outsourcing

A top an­a­lyst sees 'in­flec­tion point' in the oth­er big vac­cine race tak­ing phar­ma by storm

5 years ago
R&D

FDA may re­quire bis­pe­cif­ic an­ti­bod­ies to be com­pared with mono­spe­cif­ic prod­ucts

5 years ago
R&D
FDA+

Ve­rastem wins break­through nod for com­bo ther­a­py in ovar­i­an can­cer; EMA picks up speedy re­view of Bio­Mar­in's gene ...

5 years ago
News Briefing

Weeks out from an $80M launch, a pain and CNS start­up is back with a fresh raise. Can an IPO be far be­hind?

5 years ago
Financing

Boehringer em­barks on a PhI­II odyssey for a failed Alzheimer's drug — now re­fo­cused on schiz­o­phre­nia with new tri­al ...

5 years ago
R&D

Bi­par­ti­san House bill seeks new $30B ‘BioBonds’ loan pro­gram to rein­vig­o­rate clin­i­cal tri­als

5 years ago
Financing
R&D

NGM con­cedes key fail­ure for their lead NASH drug, clos­ing the door on a piv­otal fol­lowup — and ask­ing an­a­lysts to ...

5 years ago
R&D

Covid-19 roundup: Mod­er­na inks fill-fin­ish pact with Sam­sung Bi­o­log­ics; So­ri­ot dis­cuss­es vac­cine woes, says shot 'has ...

5 years ago
Coronavirus

In­side Ver­tex 3.0: Can Resh­ma Ke­wal­ra­mani re­peat one of biotech's biggest suc­cess sto­ries 'a­gain and again and ...

5 years ago
People
In Focus

US paus­es dis­tri­b­u­tion of Lil­ly mAb com­bo to Mass­a­chu­setts due to Covid-19 vari­ant

5 years ago
FDA+
Coronavirus

With its dengue vac­cine in the reg­u­la­to­ry queue, Take­da out­lines longterm fol­lowup da­ta that it says keep it out of ...

5 years ago
R&D

Lat­est news on J&J’s NSCLC ap­proval, Bris­tol My­ers Squibb’s big TIG­IT bet, #AS­CO21 and more

5 years ago
Weekly

J&J beats Tagris­so and Take­da to the punch in key NSCLC sub­set, pick­ing up new FDA ap­proval

5 years ago
FDA+

CVS splash­es in­to clin­i­cal tri­al ser­vices, lean­ing on lo­cal roots to change the game in terms of pa­tient en­gage­ment

5 years ago
Outsourcing

An­no­vis Bio claims wins in Alzheimer's and Parkin­son's, shares sky­rock­et; FDA de­lays de­ci­sion for Omeros' nar­so­plimab

5 years ago
News Briefing

Months af­ter burst­ing in­to the bis­pe­cif­ic scene out of nowhere, Janux fol­lows the Mer­ck hype to an IPO

5 years ago
Financing

Covid-19 roundup: Mod­er­na's jab gains ap­proval in Japan and South Ko­rea; J&J and Gavi reach agree­ment for 200M more ...

5 years ago
Coronavirus

Bris­tol My­er­s' Op­di­vo leads the pack with FDA ap­proval for re­sect­ed esophageal or GEJ can­cer

5 years ago
Pharma
FDA+

No­var­tis, BeiGene's PD-(L)1 play takes home an­oth­er win in late-stage da­ta, adding some heft to its mar­ket po­ten­tial

5 years ago
R&D

CFO tran­si­tion on the hori­zon at BioN­Tech as Sierk Po­et­ting con­cen­trates on COO du­ties; Centes­sa rides a wave of new ...

5 years ago
Peer Review

Blue­bird’s new gene ther­a­py among three new EMA OKs ahead of FDA

5 years ago
Pharma
Cell/Gene Tx

Arie Bellde­grun's vi­sion for Gink­go comes in­to view, as the now $15B com­pa­ny teams with Bio­gen on gene ther­a­py

5 years ago
Deals

Take­da tees up pri­or­i­ty re­view for sto­ried CMV drug from its $62B Shire buy­out

5 years ago
FDA+
First page Previous page 697698699700701702703 Next page Last page
A service from the Financial Times